Lee S J, Kim J S, Chee H K, Yun I J, Park K S, Yang H S, Park J H
Department of Thoracic and Cardiovascular Surgery, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Republic of Korea.
Department of Thoracic and Cardiovascular Surgery, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Republic of Korea.
Transplant Proc. 2018 May;50(4):1167-1171. doi: 10.1016/j.transproceed.2018.01.041.
The absolute shortage of donors compared with patients requiring transplantation is currently an unsolved problem, and the only possible solution may be xenotransplantation. To establish a successful clinical trial, a preclinical study using nonhuman primates is essential. Starting in November 2011, our team initiated heterotopic abdominal heart xenotransplantation, the first in the Republic of Korea. We present here the initial 7-year results.
A total of 22 xenotransplantation procedures have been performed since 2011. Single transgenic pig (alpha-galactosidase transferase knockout [GalT KO], n = 16), double transgenic pig (GalT KO + CD46, n = 3, and GalT KO + CD39, n = 2), and triple transgenic pig (GalT KO + CD46 + CD70, n = 1) models were used. Our baseline regimen of immunosuppressants comprised CD154 ab, rituximab, anti-thymocyte globulin, tacrolimus, mycophenolate mofetil, and steroids.
The mean graft survival was 16 ± 16.27 days, and the mean graft survival was significantly longer in cases performed since 2014 (7.5 ± 8.03 days vs 24.67 ± 17.50; P = .01). Although the donor heart ischemic time was decreased per annum, no correlations could be found between ischemic time and survival days of the graft. Double or triple genetic manipulated hearts exhibited significantly better survival (11.63 ± 11.29 days vs 30.83 ± 20.34 days; P = .03). When the ratio of heart weight (grams) to nonhuman primate weight (kilograms) was lower, the results tended to be better (P < .05). The rate of immediate postoperative bleeding (9%, n = 2) causing death was relatively high in the earlier period, but there have been no serious surgical complications affecting graft survival since 2013.
Investigation of effective and optimal target genes for each organ to further progression toward better results is important. In addition, the immunosuppressive regimen needs to be further studied and constantly refined.
与需要移植的患者相比,供体的绝对短缺目前是一个尚未解决的问题,唯一可能的解决方案可能是异种移植。为了开展一项成功的临床试验,使用非人类灵长类动物进行临床前研究至关重要。自2011年11月起,我们的团队开展了韩国首例异位腹部心脏异种移植。在此,我们展示最初7年的结果。
自2011年以来共进行了22例异种移植手术。使用了单转基因猪(α-半乳糖苷酶转移酶敲除[GalT KO],n = 16)、双转基因猪(GalT KO + CD46,n = 3,以及GalT KO + CD39,n = 2)和三转基因猪(GalT KO + CD46 + CD70,n = 1)模型。我们的免疫抑制剂基础方案包括CD154抗体、利妥昔单抗、抗胸腺细胞球蛋白、他克莫司、霉酚酸酯和类固醇。
平均移植物存活时间为16±16.27天,2014年以来进行的病例中平均移植物存活时间显著更长(7.5±8.03天对24.67±17.50天;P = 0.01)。尽管供体心脏缺血时间逐年减少,但未发现缺血时间与移植物存活天数之间存在相关性。双基因或三基因操作的心脏表现出显著更好的存活情况(11.63±11.29天对30.83±20.34天;P = 0.03)。当心脏重量(克)与非人类灵长类动物体重(千克)的比值较低时,结果往往更好(P < 0.05)。术后早期因立即出血(9%,n = 2)导致死亡的发生率相对较高,但自2013年以来没有严重影响移植物存活的手术并发症。
研究每个器官的有效和最佳靶基因以进一步取得更好的结果很重要。此外,免疫抑制方案需要进一步研究并不断完善。